Clifford Swan Investment Counsel LLC raised its position in Allergan (NYSE:AGN) by 16.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 39,604 shares of the company’s stock after purchasing an additional 5,582 shares during the quarter. Clifford Swan Investment Counsel LLC’s holdings in Allergan were worth $6,665,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of AGN. Renaissance Technologies LLC boosted its holdings in Allergan by 1,049.7% in the 4th quarter. Renaissance Technologies LLC now owns 726,269 shares of the company’s stock valued at $118,803,000 after purchasing an additional 663,100 shares during the last quarter. Millennium Management LLC boosted its holdings in Allergan by 277.7% in the 4th quarter. Millennium Management LLC now owns 651,755 shares of the company’s stock valued at $106,614,000 after purchasing an additional 479,174 shares during the last quarter. Swedbank boosted its holdings in Allergan by 110.7% in the 4th quarter. Swedbank now owns 740,016 shares of the company’s stock valued at $121,052,000 after purchasing an additional 388,867 shares during the last quarter. Two Sigma Advisers LP acquired a new position in Allergan in the 4th quarter valued at about $63,027,000. Finally, Polaris Capital Management LLC boosted its holdings in Allergan by 315.4% in the 4th quarter. Polaris Capital Management LLC now owns 500,200 shares of the company’s stock valued at $37,195,000 after purchasing an additional 379,781 shares during the last quarter. Institutional investors own 80.04% of the company’s stock.

In other Allergan news, CFO Matthew M. Walsh bought 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 21st. The shares were purchased at an average cost of $160.94 per share, with a total value of $321,880.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Brent L. Saunders bought 3,300 shares of the business’s stock in a transaction that occurred on Thursday, March 8th. The shares were acquired at an average cost of $152.53 per share, for a total transaction of $503,349.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 8,095 shares of company stock worth $1,258,081. 0.37% of the stock is owned by insiders.

Several equities analysts have weighed in on the stock. Leerink Swann boosted their target price on shares of Allergan from $237.00 to $242.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. JPMorgan Chase set a $265.00 target price on shares of Allergan and gave the company a “buy” rating in a report on Thursday, March 15th. Cantor Fitzgerald set a $191.00 target price on shares of Allergan and gave the company a “hold” rating in a report on Friday, April 27th. Vetr lowered shares of Allergan from a “strong-buy” rating to a “buy” rating and set a $183.43 target price on the stock. in a report on Thursday, March 15th. Finally, Deutsche Bank reissued a “buy” rating on shares of Allergan in a research note on Thursday, April 12th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and fifteen have assigned a buy rating to the company. Allergan presently has a consensus rating of “Hold” and a consensus price target of $214.81.

Shares of AGN opened at $155.25 on Thursday. Allergan has a fifty-two week low of $153.29 and a fifty-two week high of $156.87. The company has a market cap of $52.34 billion, a P/E ratio of 9.50, a price-to-earnings-growth ratio of 1.16 and a beta of 1.17. The company has a current ratio of 1.10, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36.

Allergan (NYSE:AGN) last announced its earnings results on Monday, April 30th. The company reported $3.74 earnings per share for the quarter, topping the consensus estimate of $3.36 by $0.38. Allergan had a negative net margin of 11.94% and a positive return on equity of 8.53%. The firm had revenue of $3.67 billion for the quarter, compared to the consensus estimate of $3.59 billion. During the same period in the prior year, the firm earned $3.35 EPS. The firm’s revenue for the quarter was up 2.8% on a year-over-year basis. research analysts forecast that Allergan will post 16 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 15th. Investors of record on Friday, May 18th will be paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.86%. The ex-dividend date is Thursday, May 17th. Allergan’s payout ratio is currently 17.61%.

About Allergan

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.